LIBTAYO® (cemiplimab-rwlc) Side Effects

Important Safety
Information

What is the most important information I should know about LIBTAYO?

LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems: cough, shortness of breath, or chest pain
Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tenderness
Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normal
Hormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetite
Skin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodes
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruising
Infusion reactions that can sometimes be severe. Signs and symptoms of infusion reactions may include: nausea, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swelling
Rejection of a transplanted organ. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
have received an organ transplant
have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
are pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider will give you a pregnancy test before you start treatment
- You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk with your healthcare provider about birth control methods that you can use during this time
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO
are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LIBTAYO include muscle or bone pain, tiredness, rash, and diarrhea. These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals and Sanofi at 1-877-542-8296.

Please see full Prescribing Information, including Medication Guide.

What is LIBTAYO?

LIBTAYO is a prescription medicine used to treat people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.

LIBTAYO is a prescription medicine used to treat people with a type of skin cancer called basal cell carcinoma that cannot be removed by surgery (locally advanced BCC) and have received treatment with a hedgehog pathway inhibitor (HHI) or cannot receive treatment with an HHI.

LIBTAYO is a prescription medicine used to treat people with a type of lung cancer called non–small cell lung cancer (NSCLC). LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.

It is not known if LIBTAYO is safe and effective in children.

Side effects in the LIBTAYO study

What are the possible side effects of LIBTAYO?

In 2 LIBTAYO clinical trials of 219 patients with advanced CSCC,
the most common side effects were:

74 out of 219 patients (34%)
experienced tiredness

68 out of 219 patients (31%)
experienced having a rash

55 out of 219 patients (25%)
experienced diarrhea

53 out of 219 patients (24%)
experienced muscle or bone pain

46 out of 219 patients (21%)
experienced nausea

39 out of 219 patients (18%)
experienced itching

31 out of 219 patients (14%)
experienced cough

28 out of 219 patients (13%)
experienced constipation

24 out of 219 patients (11%)
experienced joint pain

24 out of 219 patients (11%)
experienced anemia (low red blood cell count)

22 out of 219 patients (10%)
experienced vomiting

22 out of 219 patients (10%)
experienced hypothyroidism
(underactive thyroid)

22 out of 219 patients (10%)
experienced loss of appetite

Review examples of patient responses to LIBTAYO in clinical trials.

Please see full Prescribing Information, including Medication Guide.

Side effects in the LIBTAYO study

What are the possible side effects of LIBTAYO?

In 2 LIBTAYO clinical trials of 219 patients with advanced CSCC, the most common side effects were:

74 out of 219 patients (34%) experienced tiredness

68 out of 219 patients (31%) experienced having a rash

55 out of 219 patients (25%) experienced diarrhea

53 out of 219 patients (24%) experienced muscle or bone pain

46 out of 219 patients (21%) experienced nausea

39 out of 219 patients (18%) experienced itching

31 out of 219 patients (14%) experienced cough

28 out of 219 patients (13%) experienced constipation

24 out of 219 patients (11%) experienced joint pain

24 out of 219 patients (11%) experienced anemia (low red blood cell count)

22 out of 219 patients (10%) experienced vomiting

22 out of 219 patients (10%) experienced hypothyroidism (underactive thyroid)

22 out of 219 patients (10%) experienced loss of appetite

Review examples of patient responses to LIBTAYO in clinical trials.

Please see full Prescribing Information, including Medication Guide.

In 2 LIBTAYO clinical trials of 219 patients with advanced CSCC,
the most common side effects were:

74 out of 219 patients (34%)
experienced tiredness

68 out of 219 patients (31%)
experienced having a rash

55 out of 219 patients (25%)
experienced diarrhea

53 out of 219 patients (24%)
experienced muscle or bone pain

46 out of 219 patients (21%)
experienced nausea

39 out of 219 patients (18%)
experienced itching

31 out of 219 patients (14%)
experienced cough

28 out of 219 patients (13%)
experienced constipation

24 out of 219 patients (11%)
experienced joint pain

24 out of 219 patients (11%)
experienced anemia (low red blood cell count)

22 out of 219 patients (10%)
experienced vomiting

22 out of 219 patients (10%)
experienced hypothyroidism
(underactive thyroid)

22 out of 219 patients (10%)
experienced loss of appetite